

A rapid and sensitive bioelectrical biosensor for the detection of the SARS-CoV-2 S1 spike protein based on membrane-engineered cells

Presenting Author: Sophie Mavrikou

Co-Authors Georgia Moschopoulou, Vasileios Tsekouras, Spyridon Kintzios

Agricultural University of Athens/EU-CONEXUS European University, Iera Odos 75, 11855 Athens, Greece

Contact: sophie_mav@aau.gr

Abstract

As a result of the COVID-19 pandemic, novel diagnostic tools are needed to reliably monitor of infected individuals, particularly including asymptomatic patients and/or during the first days following of infection. Therefore, we developed a novel biosensor for the SARS-CoV-2 S1 spike protein antigen. The biosensor was based on measuring changes in the bioelectric responses of membrane-engineered mammalian Vero cells bearing the human chimeric spike S1 antibody, according to the principles of the Bioelectric Recognition Assay [1] and the technology of Molecular Identification through Membrane Engineering [2]. The biosensor was able to detect the viral antigen in three minutes without any prior sample processing and with a high specificity (pg/ng level) and selectivity against other virus-associated proteins. In addition, we have coupled our approach with a Point-of-Care recording device which can be operated by lay users with minimum training and operated via a smartphone.

REFERENCES

- [1] Kintzios S., E. Pistola, P. Panagiotopoulos, M. Bomsel, N. Alexandropoulos, F. Bem, I. Biselis, R. Levin, Bioelectric recognition assay (BERA), *Biosensors and Bioelectronics*, 16 (2001) 325-336.
- [2] Kokla A, Blouchos P., Livaniou E., Zikos C., Kakabakos S.E., Petrou P.S., Kintzios, S., Visualization of the membrane-engineering concept: evidence for the specific orientation of electroinserted antibodies and selective binding of target analytes, *Journal of Molecular Recognition* 26, (2013), 627-232.




Figure 1: Graphical abstract presentation of the process for developing a Bioelectric Recognition Assay for the detection of the SARS-CoV-2 S1 spike protein antigen using membrane-engineered cells as biorecognition elements.